Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04614636 · ClinicalTrials.gov registry record · Phase 1
FT538 in Subjects With Advanced Hematologic Malignancies
A Phase 1 study, sponsored by Fate Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT04614636: Clinical Trial Phase 1 study, sponsored by Fate Therapeutics.
NCT04614636 is a Phase 1 study that was terminated before completion, run by Fate Therapeutics. The registered enrollment target is 42 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04614636, a Phase 1 study, was terminated before completion, sponsored by Fate Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This is a Phase I dose-finding study of FT538 as monotherapy in acute myeloid leukemia (AML) and in combination with monoclonal antibodies in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Daratumumab
- DRUG Elotuzumab
- DRUG FT538
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2020-10-17 |
| Est. Completion | 2023-08-08 |
| Phase | Phase 1 |
Why NCT04614636 stopped before completion
NCT04614636 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% lower).
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT04614636 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04614636 about?
NCT04614636 is a clinical study titled "FT538 in Subjects With Advanced Hematologic Malignancies". This is a Phase I dose-finding study of FT538 as monotherapy in acute myeloid leukemia (AML) and in combination with monoclonal antibodies in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific c...
What is the current status of trial NCT04614636?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2020-10-17. Estimated completion is 2023-08-08.
What interventions are being tested in trial NCT04614636?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Daratumumab (DRUG), Elotuzumab (DRUG), FT538 (DRUG).
Who is sponsoring clinical trial NCT04614636?
This trial is sponsored by Fate Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04614636's enrollment target sits among peer trials
42 1105th of 2000 higher than 876 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI